key: cord-1022197-n76eb0hf
authors: Born, Jannis; Beymer, David; Rajan, Deepta; Coy, Adam; Mukherjee, Vandana V.; Manica, Matteo; Prasanna, Prasanth; Ballah, Deddeh; Guindy, Michal; Shaham, Dorith; Shah, Pallav L.; Karteris, Emmanouil; Robertus, Jan L.; Gabrani, Maria; Rosen-Zvi, Michal
title: On the Role of Artificial Intelligence in Medical Imaging of COVID-19
date: 2021-04-30
journal: Patterns (N Y)
DOI: 10.1016/j.patter.2021.100269
sha: 7bb7279a088c8f1997b939b94fdef9ba2a9f7ae5
doc_id: 1022197
cord_uid: n76eb0hf

Although a plethora of research articles on AI methods on COVID-19 medical imaging are published, their clinical value remains unclear. We conducted the largest systematic review of the literature addressing the utility of AI in imaging for COVID-19 patient care. By keyword searches on PubMed and preprint servers throughout 2020, we identified 463 manuscripts and performed a systematic meta-analysis to assess their technical merit and clinical relevance. Our analysis evidences a significant disparity between clinical and AI communities, both in the focus on imaging modalities (AI experts neglected CT and Ultrasound, favoring X-Ray) and performed tasks (71.9% of AI papers centered on diagnosis). The vast majority of manuscripts were found deficient regarding potential use in clinical practice, but 2.7% (N=12) publications were assigned a high maturity level and are summarized in greater detail. We provide an itemized discussion of the challenges in developing clinically relevant AI solutions with recommendations and remedies.

The recent acceleration of publications intersecting AI and imaging for COVID-19, brings a need for rigorous comparative evaluation of papers to summarize and highlight trends to a broad clinical audience. Previous review papers on COVID-19 either focused on a technical assessment of AI in imaging 6 or elaborated on the role of imaging 1 . Related systematic reviews were either not devoted specifically to imaging , 17, 18 or used extremely small sample sizes (N=11) 19 . In contrast, this paper attempts to bridge clinical and technical perspectives by providing a comprehensive overview to guide researchers towards working on the most pressing problems in automating lung image analysis for COVID-19. Most related to our work, Roberts et al. 20 very recently conducted a systematic review of 62 studies and claims that none of the models are of potential clinical use.

While the objective of our work is similar and we also find that the vast majority of manuscripts suffers from methodological flaws, we identify 12 publications which meet substantially higher standards than the remaining manuscripts. Moreover, this work is less focused on assessing individual contributions and more on extracting current trends in the field in a rigorous and comprehensive manner.

Overall, we herein provide the, to date, largest systematic meta-analysis of AI in MI of COVID-19.

Manually analysing 463 publications throughout all of 2020, we attempt to draw a cohesive picture on the current efforts in the field and highlight future challenges, especially related to the cooperation of clinicians and AI experts. While we focus on the lung as the primary organ of SARS-CoV-2 infection, we note the significance of extrapulmonary manifestations 21 . To discover trends from the overwhelming research activities in COVID-19, AI and MI, a systematic review and meta-analysis were performed according to the PRISMA guidelines 22 .

Literature, indexed in PubMed and three preprint servers, namely, arXiv, bioRxiv and medRxiv, were queried. The process is illustrated in Figure 1 (left) and shows two main streams of queries: a broad one using "AI" AND "COVID-19" AND "Medical Imaging" and a modality-specific one with "AI" AND "COVID-19" AND "Lung" AND ("CT" OR "CXR" OR "US"). Following PRISMA guidelines, we combined the results of both queries across all databases leading to the identification of 463 papers about AI on lung imaging for COVID-19. These papers were included in a manual meta-analysis to review the maturity of the AI technologies and the trends in the rapidly evolving field (for the detailed procedure and a list of synonyms used see appendix Table A1 ). The publications about AI technology typically tend to report a proof of concept, an illustration of a success in a non-clinical setting, or a report of clinically successful experiments. Additionally, many of the papers identified were not published in peer reviewed journals. To evaluate the maturity of papers, we included five criteria that were assessed rigorously (Figure 1(right) ).

Whether or not the paper appeared in a peer-reviewed journal or conference.

The complexity and the performance of the developed AI framework. Internal, clinical data is preferred over public datasets and multi-hospital/multimodal data is valued. 4 . Experimental rigor: Stringency in the evaluation and comparison of the methodology.

The deployment and adoption of the solution in hospitals.

Comparison studies of AI and radiologists or deployment of web services were also rewarded.

The peer review score was binary and all other categories were scored ternarily (0, 0.5, 1). Details on the scheme with examples can be found in the supplementary material. The decision function for maturity level (Figure 1 (right)) guarantees that publications that received a "0" in one of the 5 categories cannot get a high maturity score (implying that e.g., preprints are never highly mature).

Moreover, we manually inferred the most common tasks addressed in the AI papers, such as detection, segmentation, characterization and outcome prediction, and mapped them into three main clinically relevant categories: diagnosis, severity assessement and prognosis, and one technical task: segmentation. The segmentation papers discuss localization of lung tissue or other disease features without direct applications to any clincially relevant downstream tasks.

For publications that focused on several categories, we consider the primary task only. For example, a number of publications classified as "diagnosis" or "severity assessment" utilized segmentation methods on the fly. Papers that provided a review of ML for MI on COVID-19 and did not introduce original new technoglogy were labeled as "review" papers and excludued from the maturity assessment, leading to 437 reviewed papers. The remaining evaluation criteria per publication were imaging modality, country of authors and country of data source. For each paper, we also recorded the total number of citations indicated on Google Scholar as of 28.2.2021 and converted it to the monthly citation rate. Note that the meta-analysis was blindfolded to the number of citations.

The publication keyword search was performed using our toolbox paperscraper that was developed during this project and is open-sourced * .

In recent years, AI solutions have shown to be capable of assisting radiologists and clinicians in detecting diseases, assessing severity, automatically localizing and quantifying disease features or providing an automated assessment of disease prognosis. AI for MI has received extraordinary attention in 2020, as attested by a multitude of interdisciplinary projects attempting to blend AI technologies with knowledge from MI in order to combat COVID-19. A keyword search combining AI and MI revealed 2563 papers in 2019, while 2020 has seen more than twice such papers (5401, cf. Figure 2 ). Out of these publications, 827 are related to COVID-19, indicating that COVID-19 has accelerated the development of AI in MI.

To enable a perspective on the emergence of AI for MI of COVID-19, we have compiled a comparison on the progress of automatic analysis in breast and lung imaging, as defined in the literature above, from between 2017 and 2020. Figure 3 (left) shows a stable growth of papers in AI on both lung and breast imaging over the years 2017-2019. In 2020, the rise of lung-related papers has been accelerated by COVID-19 with a doubling in the first half of 2020 compared to H2 2019 as well as a doubling of 2020 compared to 2019, whereas the trend on AI on mammography imaging remained unaltered compared to previous years. a stable   trend of ~100-120 papers per quarter on AI whereas with the COVID-19 outbreak in 2020, numbers   soared to 164, 352, 372 and 405 papers for Q1-Q4, 2020 respectively. This rise was spontaneously evoked by COVID-19, as excluding papers mentioning COVID-19 would have resulted in a continuation of the stable trend (see lightly shaded bars) of a hypothetical ~120-160 publications.

Notably, the relative contributions of the modalities changed toward CXR from 2019 to 2020 (shares of 71% vs 63% for CT, 27% to 35% for CXR and 2% for US respectively). Moreover, for non-COVID-19 papers, the ratio between preprints and PubMed indexed papers for AI in breast and chest is 29% and 37% from 2017-2019, respectively; for COVID-19 related papers, this ratio rose to 58%.

By focusing on CT, CXR and US, we quantified the publication efforts of AI for MI of COVID-19 and identified 463 papers which were included in a manual meta-analysis to review the maturity of the AI technologies and the trends in the rapidly evolving field. The full spreadsheet with individual scores for each publication is available in the supplementary material.

Of the 4977 papers about MI and COVID-19 (see Figure 2 (right)), 2496 are specific to modalities as shown in Figure 4 (left), indicating a dominance of CT in clinical papers (84%), followed by CXR (10%) and LUS (6%). By using publication counts as an indirect indicator on scientific response, we observe a mismatch in the focus of the AI community in comparison to the clinical community as illustrated by the distribution of papers per modality in Figure 4 (right) that shows a clear dominance of CXR (50%) across AI papers.

In addition, the vast majority (72%) of papers focused on diagnosis of COVID-19 over tasks like severity and prognosis ( Figure 5 (left) ). This trend is in contrast to the ACR guidelines appraising J o u r n a l P r e -p r o o f imaging as an inconclusive test for COVID-19 detection due to uncertainties in accuracy and risk of cross-contamination. Revealing was the unanimous use of CXR data (50%, see Figure 4 (right)) that was commonly utilized without any further clinical or radiomic features. The tendency for diagnosis was especially prominent for CXR versus CT where 87% and 58% diagnosis papers were found respectively (cf. the sunburst plot showing task and maturity as distributed by modality in the supplementary material, Fig. A1 ). While 6% of papers (27 of all 437 non-review papers) exploited multimodal imaging data towards building their AI models, studies on multimodal imaging data of the same patient cohort are lacking with few exceptions. In one example manual disease airspace segmentation from CT was used as ground truth for volumetric quantification from CXR 23 . Another study demonstrated the diagnostic accuracy (ROC-AUC) of AI on CT to be clearly superior to CXR 30 .

The maturity of the papers was assessed following the scheme in Figure 1 (right) by co-authors who have developed or worked with DL algorithms (see Figure 5 (middle)). Almost 70% of papers were assigned a low maturity level and only 12 (2.7%) highly mature studies were identified. A detailed spreadsheet with the evaluations of each paper is included in the supplementary material.

CT papers had a higher maturity score than CXR papers (2.1 +-1.3 vs. 1.3 +-1.1, p<1e-11, MWU) and 57% of CT versus 43% of CXR papers were peer-reviewed. As the pandemic continues the preprint ratio is declining steadily (from 69% in Q1 to 45% in Q4) but not (yet) significantly (r=-0.93, p=0.07). The maturity score also heavily varies across performed task and was significantly higher for COVID-19 severity assessment and prognosis (2.4 and 2.5) compared to diagnosis/detection (1.5) and segmentation (1.6) as assessed by post-hoc Tukey's HSD multiple comparison tests (see Figure 6 ).

Posteriori, we observed that the monthly citation rate was significantly greater for 1) high compared to medium maturity papers (6.9 vs. 2.3, p<0.01, U) and 2) medium compared to low maturity (2.3 J o u r n a l P r e -p r o o f vs. 1.9, p<0.05, U). The continuous maturity score was found to be significantly correlated (r=0.12, p<0.05) with the monthly citation rate. Interestingly however, a major factor accounting for a high citation rate is not the maturity but the months elapsed since publication (r=0. 35, p<1e-14) . This suggests that absolute citations and relative citation rates are insufficient quality measures and we instead observe a tendency towards continuous citation of publications that appeared early in the pandemic (irrespective of their quality).

We observed that only 30% of papers used proprietary or clinical data ( Figure 5 (right)), while almost 70% analysed publicly available databases. Such databases exist for CT 24 , CXR 25 and LUS 26 and are usually assembled by AI researchers, contain data fetched from publications and are comprised of no more than a few hundred patients from heterogenous sources/devices without detailed patient information. Accordingly, the geographical diversity of data sources was not extremely high (26 countries), and by a wide margin the three most important data donators were countries hit early from the pandemic, namely, China (48%) and, to a lesser extent, USA (12%) and

Italy (11%). Interestingly, a global collaborative spirit towards combatting COVID-19 was revealed as first-authors from 53 countries and 6 continents contributed to the researchwith the most active countries being China (21%), USA (13%) and India (11%).

12 (2.7%) of the assessed papers were assigned high maturity 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 . The list of papers together with details about their task, key finding, implementation and results appear in Table 1 and are further discussed in this section.

We summarize the trends observed in the identified list of mature papers with a deeper focus on 

In this section, we discuss the four categories of tasks addressed by the 463 papers chosen for metaanalysis, namely: diagnosis, severity, prognosis and segmentation. We also highlight key results from the 12 mature publications and provide an overview of the findings specific to COVID-19.

We find that 72% of the papers centered on COVID-19 diagnosis with 8 out of the 12 mature papers (75%) also addressing this task. As the most prominent COVID-19 test relies on the identification of viral RNA using RT-PCR 39 , imaging is not routinely performed/recommended for diagnosis and given its reliance on pulmonary pathologies, it is especially inappropriate for J o u r n a l P r e -p r o o f detection of early or asymptomatic infections 40 . However, compared to nucleic acid tests, CTs may be more sensitive at a single time point for the diagnosis of COVID-19 41 . A key diagnostic challenge is the non-specificity of COVID-19 patterns and their differentiation from non-COVID-19 viral pneumonia 42 . Here, non-imaging assessments like anamnesis can contribute to the diagnosis. Secondly, asymptomatic patients with unaffected lungs are notoriously challenging to be detected. In both cases, however the lack of visibly distinguishing features for COVID-19 might not directly imply a limited ability of DL-based approaches, which might still be able to automatically identify (segment) distinguishing features, given the appropriate data for training 43 .

As it has been demonstrated, if DL approaches combine CT and clinical features, the performance of radiologists in the detection of symptomatic COVID-19 patients can be matched 28 (or surpassed 34 ), and even asymptomatic patients with normal CT scans can be identified in 68% of the cases 28 .

Moreover, multiple studies validated that radiologists' performance improves upon consultation of AI: Junior radiologists along with AI can perform as well as mid-senior radiologists 27 and radiologists' sensitivity and specificity can improve by nearly 10% through AI 44 .

In another study, AI recovered full-dose CT from ultra-low-dose CTs with a satisfying acceptance score of 4.4 out of 5 by radiologists (compared to 4.7 and 2.8 for full-and ultra-low-dose respectively) and thus helped to reduce the CT radiation dose by up to 89% while still facilitating downstream diagnosis 45 . One highly mature diagnostic study using CXR included almost 6000 scans from >2000 COVID-19 patients and their DL model exceeded the diagnostic performance of thoracic radiologists as found by significantly higher area under the curve of 0.94 (vs. 0.85) and

sensitivities when matching specificity to radiologists' performance 36 .

Imaging findings of COVID-19 patients correlate with disease severity 46 and CT scanning can assess the severity of COVID-19 and help monitor disease transformation among different clinical conditions 47 . A retrospective comparison of imaging findings on chest CTs with disease severity revealed an increased occurrence of consolidation, linear opacities, crazy-paving pattern and bronchial wall thickening in severe patients at a higher frequency than in non-severe COVID-19 patients. The CT findings correlated with several worse symptoms, including a respiratory rate greater than 30 breaths per minute, and oxygen saturation of 93% or less in a resting state among other phenotypes 48 . In clinical practice, often progress assessments as well as patient management is performed based on CXR and not chest CT. AI that provides assessment of severity could be useful if it was quantifiable and accurate but only one publication was found mature in performing this task 37 . The authors developed a clinically useful AI tool consisting of a U-Net backbone for lung segmentation and quantification of pulmonary opacity within 10 days and achieved human-level performance when training on less than 200 CT scans 37 . Another work utilized a dataset of multiple CT scans per patients and introduced a "CT scan simulator" that modelled the temporal evolution of the CT through disease progression and was evaluated on multi-national and multi-machine data 49 . Their work proposed to decompose the task of CT segmentation from one 3D into three 2D problems, thus achieving remarkable 

Very few of the papers (26 i.e., 6%) focused on prognostic assessments of COVID-19 such as treatment outcome prediction, risk assessment (e.g., requirement for ICU admission or mechanical ventilation) or time elapsed to negative PCR. However, two of them were assessed as mature 27, 29 and the average maturity score was the highest for this task (cf. Figure 6 ).

However, in contrast to diagnosis, these tasks are clinically more relevant as they cannot be performed routinely and reliably with standard care. While this can be attributed to an overall gap in knowledge of the long-term effects of COVID-19 and a lack of historical data to enable training on large scale prognosis data, it is constructive towards the alignment of future research in the field. On the other side, in the past few months the hyper-inflammatory response induced by COVID-19 has been identified as a major cause of disease severity and death 52 . Thus, studies have focused on the identification of predictive biomarkers of pathogenic inflammation. Lung imaging is not expected to reflect these biomarkers' expression, leading to limited prognosis accuracy based on imaging.

One study assessed as highly mature, seamlessly integrated a diagnostic module (based on a CT lung-lesion segmentation) with a prognostic module that combined clinical metadata and quantification of lung-lesion features 27 . The system demonstrated diagnostic performance comparable to a senior radiologist and the prognostic module predicted progression to critical illness and could evaluate drug treatment efficacy by three drugs. Notably, the multi-center dataset of 3,777 patients as well as the source code is available to the public to support the development of a better system and to validate their study. 

In summary, the number of papers on AI in MI for COVID-19 has grown exponentially in 2020 and the quality of the manuscripts varies significantly. In our manual review, only 12 (2.7%) highly J o u r n a l P r e -p r o o f mature studies were identified. A key characteristic that underpins highly mature studies is an interdisciplinary and often multi-national collaboration of medical professionals and computer vision researchers.

Given the observed disparities between the AI and medical communities, we discuss several challenges that are currently encountered in such interdisciplinary collaborations and provide potential approaches to remedy the same.

The AI literature primarily addresses diagnostic tasks as opposed to other tasks with higher clinical relevance, such as monitoring/severity estimation (which tracks with clinical outcomes) and management tasks such as ventilation equipment and bed allocation. Currently, even the best AI solutions have minimal performance gains on well-defined tasks (such as diagnosis) and are thus unlikely to be adopted clinically 8 .

Conclusions from our meta-analysis are that (1) the choice of task is critically driven by the availability of annotated data and (2) 57 should be followed and complemented by an increased motivation among AI experts to focus on the right questions and leverage suitable, and radiologists-friendly, inductive biases like soft labelling 58 35 and (2) using DL to help evaluate treatment outcomes, e.g., by assessing changes in lesion size and volume changes 27 .

While most authors of highly mature studies released their code (indeed three papers did not release Privacy-preserving data science techniques have advanced 65 and should help to build more trust toward data sharing.

Federated learning (FL) is an emerging realm of ML concerned with distributed, decentralized training that stores privacy-sensitive data only locally (for details see 66, 67, 68 ) . It allows multiple parties to collaboratively train the same model without data sharing and could thus become key to foster collaborations between clinical and AI communities and overcome privacy concerns. Our meta-analysis included three preprints exploring FL using CT 69 or CXR 70 data. A recent FL study on EHR from 5 hospitals was found to improve COVID-19 mortality prediction 71 . These efforts will hopefully increase reproducibility and make comparative studies more feasible, which will help the research community focus on the highest performing methods.

J o u r n a l P r e -p r o o f

An ideal imaging modality should be safe, ubiquitous, accurate, fast, and preferably provide highquality reproducible results via portable devices. The three different imaging modalities, addressed in this study, differ in their clinical use, their availability, portability, safety and reproducibility and none of them is ideal for addressing all aspects of the pandemic (for a comparison see Table 2 ). For a geographic map showing the regional market sizes of the modalities see the Supplementary Material ( Figure A2 ). Herein, we have unravelled a mismatch in the number of publications per modality between clinical and AI communitiesthe AI literature has focused mostly on CXR whereas CT and LUS have received comparably little attention (cf. Figure 4) . CT is deemed the gold-standard, dominates in clinical publications, is more sensitive than CXR for detecting diseases of the chest, but is restricted to modern medical facilities 72 . CXR is notoriously less sensitive than CT 73 , yet it is the most abundantly used modality across the globe when managing COVID-19

patients. While CXR can underestimate disease, CT can narrow down a differential diagnosis that appears broad on CXR. For AI, large data sets are needed for ML approaches, and there are much larger data sets for CXR than for CT.

As the use of imaging is less regulated compared to PCR/antigen testing, an official recognition of all imaging modalities by leading institutions and stakeholders is needed. In conjunction with clear guidelines for clinicians on when to use which modality, trust into imaging can be increased and workflows can be streamlined. For example, the practical advantages of LUS include noninvasiveness and portability and its consequent role in triage 74 . However, LUS is operator dependent and requires close patient contact for a relatively longer time 75 . It was described as a preferred modality in Italy 76 during spring 2020, but it is not used as extensively in other geographies, mainly applied for patients with CT/CXR contraindications and predestined to study solid organs unlike the lung. Notably, LUS sensitivity was found higher than CXR for COVID-19 diagnosis 77 , and some even found comparable diagnostic accuracy to CT 78, 79 . However, the role of J o u r n a l P r e -p r o o f LUS for the COVID-19 pandemic is still actively debated 80,81 ,82 and, regarding AI, with only one publicly available dataset 26 more research is needed to narrow down the practical role of AI on LUS 26, 51, 83, 84 . Additionally, studies using ML on multiple imaging modalities from the same cohort are certainly needed to shed light on comparative questions between modalities from the perspective of ML. The performance of AI-assisted radiologists in detecting COVID-19 might or might not confirm the current radiologic findings, for example that CXR is less sensitive than CT 85 and LUS (when compared to RT-PCR 86 or CT 87 ) or that B-lines are the most reliable pathological pattern across CT, CXR and LUS 88 . From the AI perspective, LUS is presumably the modality with the highest improvement potential in medical image analysis in the near future. Ultimately, AI technology focusing on plain CXR/LUS data may enable wider leverage in developing countries with limited medical resources

The combined lack of robustness and interpretability poses steep challenges for the adoption of AI models in clinical practice 89 . Models trained without optimizing for reliability typically make overconfident wrong predictions or under-confident right predictions, especially when extrapolating data. In order to ensure that models make decisions for the right reasons, they must be trained to recognize out-of-distribution samples, and handle distribution shifts. Thereby, allowing models to abstain from making predictions when it is unsure, and deferring such samples to the experts. reasoning has found its way into ML explainability 95 , opened doors toward contrastive explanations (by ascribing how changing the input would affect predictions) and can readily be combined with uncertainty quantification principles to build models integrating reliability into the optimization process 96 . This will enable model introspection and facilitate human-in-the-loop analysis while also considering the performance distribution among human evaluators.

A standard healthcare AI project workflow involves defining a use-case, curating data and annotations, identifying problem constraints, choosing relevant metrics, designing and building the AI system, and lastly evaluating the model performance (see Figure 7 top). However, any problem involves many stakeholders: patients, ethics committee, regulatory bodies, hospital administrators, clinicians and AI experts 97 . In general, data-driven constraints identified by the AI experts tend to transform the clinical task into an evolved task. This in combination with the disconnect of other parties (e.g., clinicians, patients) in the build lifecycle causes potential gaps in the overall outcomes of the collaboration. Awareness and understanding of the difference in needs, motivations, and solution interpretations across agents is imperative. For example, for clinicians, generation of data and metadata are cumbersome, time demanding and tedious. What drives and motivates clinicians are improved clinical workflows and the knowledge and better understanding the analysis can bring, so that they can provide improved patient care. Moreover, AI models may hide inherent risks such as the codification of biases, the weak accountability, and the bare transparency of their decisionmaking process. Therefore, the way AI models are evaluated can have multiple implications on their applicability, generalization and translation to clinical practice 97, 98 . To this end, both the definition of the task to be implemented and evaluated, but also the types of metrics to be leveraged to evaluate the results' outcomes can be different across collaborators, and hence must be collectively defined.

We illustrate such an improved workflow that incorporates other stakeholders in the build process, robust metrics, and iterative useability studies in Figure 7 (bottom). We believe that such a workflow could critically improve the quality of collaboration between AI and clinicians.

To enable agile and transparent development with continuous feedback and evaluation loops, new conducive environments are necessary. A collaboration environment that enables sharing of data, code and results, but also immediate feedback and discussion platforms across collaborators is essential. Communities of discovery such as the digital mammography DREAM challenge 99 

The role of imaging in the detection and management of COVID-19: a review

COVID-19 diagnosis and management: a comprehensive review

The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society

ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. ACR website. Advocacy-and Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CTfor-Suspected-COVID19-Infection

COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review

Review of artificial intelligence techniques in imaging data acquisition, segmentation and diagnosis for covid-19

Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal

An awakening in medicine: the partnership of humanity and intelligent machines

Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study

Predicting breast cancer by applying deep learning to linked health records and mammograms

International evaluation of an AI system for breast cancer screening

Artificial intelligence in breast imaging

OPTIMAM Mammography Image Database: A Large-Scale Resource of Mammography Images and Clinical Data

CheXpert: A Large Chest Radiograph Dataset with Uncertainty Labels and Expert Comparison

End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography

The present and future of deep learning in radiology

Role of Machine Learning Techniques to Tackle the COVID-19 Crisis: Systematic Review

Early survey with bibliometric analysis on machine learning approaches in controlling COVID-19 outbreaks

Systematic review of artificial intelligence techniques in the detection and classification of COVID-19 medical images in terms of evaluation and benchmarking: Taxonomy analysis, challenges, future solutions and methodological aspects

Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans

Extrapulmonary manifestations of COVID-19

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Automated Detection and Quantification of COVID-19 Airspace Disease on Chest Radiographs: A Novel Approach Achieving Expert Radiologist-Level Performance Using a Deep Convolutional Neural Network Trained on Digital Reconstructed Radiographs From Computed Tomography-Derived Ground Truth

SARS-CoV-2 CT-scan dataset: A large dataset of real patients CT scans for SARS-CoV-2 identification

Covid-19 image data collection: Prospective predictions are the future

Accelerating Detection of Lung Pathologies with Explainable Ultrasound Image Analysis

Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography

Artificial intelligence-enabled rapid diagnosis of patients with COVID-19

AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia

Development and evaluation of an artificial intelligence system for COVID-19 diagnosis

Relational modeling for robust and efficient pulmonary lobe segmentation in CT scans

AI-assisted CT imaging analysis for COVID-19 screening: Building and deploying a medical AI system

Automated assessment and tracking of COVID-19 pulmonary disease severity on chest radiographs using convolutional siamese neural networks

Artificial Intelligence Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT

Automated Assessment of CO-RADS and Chest CT Severity Scores in Patients with Suspected COVID-19 Using Artificial Intelligence

Diagnosis of covid-19 pneumonia using chest radiography: Value of artificial intelligence

Development and clinical implementation of tailored image analysis tools for COVID-19 in the midst of the pandemic: The synergetic effect of an open, clinically embedded software development platform and machine learning

Dual-branch combination network (DCN): Towards accurate diagnosis and lesion segmentation of COVID-19 using CT images

COVID-19 diagnosis and management: a comprehensive review

Laboratory diagnosis of COVID-19: Current issues and challenges

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Current Concepts Imaging in COVID-19 and the Challenges for Low and Middle Income Countries The Journal of Global Radiology Imaging findings

Artificial intelligence distinguishes covid-19 from community acquired pneumonia on chest ct

End-to-end automatic differentiation of the coronavirus disease 2019 (COVID-19) from viral pneumonia based on chest CT

Ultra-low-dose chest CT imaging of COVID-19 patients using a deep residual neural network

Use of chest imaging in COVID-19: a rapid advice guide

Computed Tomographic Features and Short-term Prognosis of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Single-Center Study from Kashan, Iran

Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease

A rapid, accurate and machine-agnostic segmentation and quantification method for CT-based COVID-19 diagnosis

Determination of disease severity in COVID-19 patients using deep learning in chest X-ray images

Modality alignment contrastive learning for severity assessment of COVID-19 from lung ultrasound and clinical information

An inflammatory cytokine signature predicts COVID-19 severity and survival

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study

Automated quantification of CT patterns associated with COVID-19 from chest CT

Comparative study of deep learning methods for the automatic segmentation of lung, lesion and lesion type in CT scans of COVID-19 patients

A noise-robust framework for automatic segmentation of covid-19 pneumonia lesions from ct images

Towards better clinical prediction models: seven steps for development and an ABCD for validation

Learning classification models with soft-label information

Transparency and reproducibility in artificial intelligence

An interpretable mortality prediction model for COVID-19 patients

External validation demonstrates limited clinical utility of the interpretable mortality prediction model for patients with COVID-19

Replication of a mortality prediction model in Dutch patients with COVID-19

Limited applicability of a COVID-19 specific mortality prediction rule to the intensive care setting

The need for open source software in machine learning

Integrating blockchain for data sharing and collaboration in mobile healthcare applications

Federated machine learning: Concept and applications

The Value of Federated Learning During and Post COVID-19

Federated Learning of Electronic Health Records to Improve Mortality Prediction in Hospitalized Patients With COVID-19: Machine Learning Approach

Blockchain-federated-learning and deep learning models for covid-19 detection using ct imaging

Experiments of federated learning for covid-19 chest x-ray images

Federated Learning of Electronic Health Records to Improve Mortality Prediction in Hospitalized Patients With COVID-19: Machine Learning Approach

The industry of CT scanning

Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients

Point-of-care lung ultrasound in patients with COVID-19--a narrative review

Use of Chest Imaging in the Diagnosis and Management of COVID-19: A WHO Rapid Advice Guide

Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19

Point-of-care Lung Ultrasound Is More Sensitive than Chest Radiograph for Evaluation of COVID-19

Diagnosing COVID-19 pneumonia in a pandemic setting: Lung Ultrasound versus CT (LUVCT) A multi-centre, prospective, observational study

Correlation between Chest Computed Tomography and Lung Ultrasonography in Patients with Coronavirus Disease 2019 (COVID-19)

Correlation between Chest Computed Tomography and Lung Ultrasonography in Patients with Coronavirus Disease 2019 (COVID-19)

COVID-19 outbreak: less stethoscope, more ultrasound

POCUS in COVID-19: pearls and pitfalls

Development of a convolutional neural network to differentiate among the etiology of similar appearing pathological B lines on lung ultrasound: a deep learning study

Semi-Supervised Active Learning for COVID-19 Lung Ultrasound Multi-symptom Classification

Diagnostic accuracy of X-ray versus CT in COVID-19: a propensity-matched database study

Point-of-care lung ultrasound is more sensitive than chest radiograph for evaluation of COVID-19

6 Lung Ultrasound versus Chest X-ray for the Diagnosis of COVID-19 Pneumonia

COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review

On the Interpretability of Artificial Intelligence in Radiology: Challenges and Opportunities

Grad-cam: Visual explanations from deep networks via gradient-based localization

Striving for Simplicity: The All Convolutional Net. ICLR (Workshop)

Dropout as a bayesian approximation: Representing model uncertainty in deep learning

Exploring uncertainty measures in deep networks for multiple sclerosis lesion detection and segmentation

Test-time data augmentation for estimation of heteroscedastic aleatoric uncertainty in deep neural networks

Counterfactuals in Explainable Artificial Intelligence (XAI): Evidence from Human Reasoning

Uncertainty for Safe Utilization of Machine Learning in Medical Imaging, and Graphs in Biomedical Image Analysis

Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies

Key challenges for delivering clinical impact with artificial intelligence

Evaluation of combined artificial intelligence and radiologist assessment to interpret screening mammograms

OECD Science, Technology and Innovation Outlook 2021

International collaboration during the COVID-19 crisis: autumn 2020 developments

During the COVID-19 pandemic, medical imaging (CT, X-Ray, ultrasound) takes a key role in addressing the magnified need for speed, low cost, ubiquity, and precision in patient care. The contemporary digitization of medicine and rise of artificial intelligence (AI) induce a quantum leap in medical imaging: AI has proven equipollent to healthcare professionals across a diverse range of tasks and hopes are high that AI can save time and cost and increase coverage by advancing rapid patient stratification and empowering clinicians. This review bridges medical imaging and AI in the context of COVID-19 and conducts the largest systematic review of the literature in the field. We identify several gaps and evidence significant disparities between clinicians and AI experts and foresee a need for improved, interdisciplinary collaboration to develop robust AI solutions that can be deployed in clinical practice.The key challenges on that roadmap are discussed alongside recommended solutions.

This is the largest systematic review on the role of AI in medical imaging of COVID-19 In medical imaging, artificial intelligence (AI) has the potential to save time and cost in the healthcare system by advancing rapid patient stratification. We conducted the largest systematic review (N=463) of AI methodology on medical imaging data from COVID-19 patients. AI experts largely failed to focus on clinically relevant tasks and imaging modalities and only few publications are found valuable. On the roadmap toward developing robust and clinically valuable AI solutions, we identify key challenges and provide possible remedies.